课件 Medchem(2012)-13b(process development,medchemists,green chemistry, pollution and resources)

合集下载

酶工程

酶工程

实用精品课件PPT
16
趋势判断和需求分析
目前生物催化技术已成为各公司争夺的目标并且已成 为一些公司谋求发展和提升地位的工具 。
Degussa、DSM、Roche、BASF、Dow、Lonza等许 多跨国公司都在积极采取措施,扩大他们在生物催化 领域里的生产能力。
实用精品课件PPT
17
生物催化发展的主要推动力
2002年全球转基因植物种植面积达5870万公顷,16 个国家600万农民以种植转基因作物为主
预计到2020年全球转基因作物的种植面积将超过天然 作物
实用精品课件PPT
7
工业生物技术产业
能源生物技术 环保生物技术 生物材料:聚交酯、聚乳酸、生物钢 提升传统产业:化学工业、制药工业、发酵工
核心目标:大规模利用生物体系(如细胞或酶)作为 催化剂实现物质转化
工业生物技术是生物技术的重要组成部分
实用精品课件PPT
9
工业生物技术发展空间
提升传统产业 生物能源 环境生物技术 生物材料
实用精品课件PPT
10
典型工业生物技术过程
细胞

生物催化剂 (游离或固定化)
空气Βιβλιοθήκη 检测控 制仪表除 菌
产品提取纯化
实用精品课件PPT
22
生物催化剂工程技术瓶颈
对生物催化剂作用机理缺乏深入的认识 对次级代谢产物代谢途径(包括途径间相互关系)缺
乏理解 细胞工程化的方法十分有限(即代谢工程) 生产酶和辅因子的成本过高
实用精品课件PPT
23
当前生物催化的研究热点
新酶或已有酶的新功能的开发 根据已有底物开发新的酶反应 利用突变或定向进化技术改善生物催化剂性能 利用重组DNA技术大规模生产生物催化剂 利用有机溶剂或共溶剂开发新的反应体系 体内或体外合成的多酶体系 克服底物和产物抑制 精细化工品或医药合成技术的放大 辅因子再生 生物催化剂的修饰

课件 Medchem(2012)-1c(introduction jobs cuts and empolyments)

课件 Medchem(2012)-1c(introduction jobs cuts and empolyments)

1Pharmaceutical Diaspora : Highly experienced Bayer chemists encounter challenging job market By Lisa M. JarvisChemical & Engineering News April 16, 2007 Volume 85, Number 16 , pp. 27-30A Ghost Town :Pharmaceutical research at Bayer's West Haven site in Connecticut ended in January 2007 (Note: In June 2007, Yale University purchased the entire campus for biotechnology, medical and other life sciences research).Company Cutbacks At US R&D Sitesin 2006 and part of 2007February 2006: Procter & Gamble drops discovery-phase R&D, costing 300 scientific jobs at its Mason, Ohio, site.February 2006: Johnson & Johnson closes its Raritan, N.J., drug discovery unit, which employed 280 people.June 2006: Johnson & Johnson closes its Freemont, Calif., biopharmaceutical operations, affecting 500 jobs.November 2006: Bayer closes R&D sites in West Haven, Conn., and Richmond, Calif., affecting 600 scientists.January 2007: Pfizer shutters three R&D sites in Michigan as part of a plan to cut 10,000 jobs globally.February 2007: Abbott Laboratories cuts 200 jobs, primarily scientists working at its Lake County, Ill., facility.357911AZ A&D at Charnwood131517Drugs that were successfully developed at the Sandwich site:Norvasc(amlodipine), Heart drugCelsentri(maraviroc), HIV drugViagra(sildenafil), ED drugDiflucan(fluconazole), Antifungal drug“My point of view is there are nosacred cows in this portfolio.”Ian C. Reed, CEO, Pfizer1921AstraZeneca is cutting a further 7,300 jobs, with 2,200 in R &D23 AstraZeneca Press Release, 2 February 2012The Sanofi Aventispharmaceuticals factoryin Fawdon, Newcastle, isto close in 2015 with theloss of up to 450 jobs,according to the unionUnite.Staff left the plant and wenthome for the day, some ofthem in tears, after theannouncement was made.One told Sky Tyne andWear: "I am absolutelydevastated, I don't knowwhat we're going to do."The site previouslybelonged to SterlingOrganics.25 26 June 2012: Rocheannounced the closure of theNutley site in New Jersey withthe loss of 1000 R&D jobs.274 September 2012: Merck KGaA is spreading the job-cutting pain to its home country. The company plans to slash 1,100 jobs from its German payroll by 2015, or about one-tenth of its workforce there. Some manufacturing operations will be discontinued, but Merck has agreed with labor leaders to cut most of the jobsin a "socially acceptable manner," through early retirements and voluntary-resignation deals.29 2011年全球大药企解雇职工排名31 Science career in medicinal chemistrya perspective from American Chemical Society in 2005 From: American Chemical Society, Education DivisionThe Pay Scale for Chemist (including medicinal chemist)The Pay ofCEOs in theBig Pharma33A Perspective on the Changing Role ofChemistry in Drug Discovery◆With seemingly endless mergers and acquisitionsand the advent of countless start-ups with abiological spin, it seems that there will be greaterdiversity than at any point in the history of thePharma industry.◆However, closures in Europe and US and theoutsourcing and relocation of R&D to low-costregions by Pharma will also play a role in theglobalisation of the industry and a shift away fromthe West as the powerhouse of drug discovery.◆Indeed, while in the past academia seems to havedriven fundamental science, discovery isincreasingly the focus of academics and they toohave increased their patent output substantiallyduring the last ten years, their collaborators, andspin-out companies, while development becomesthe remit of the industry.The future: Academiaor Industry?or Nowhere??35What has changed for chemists in ten years time (in the US)? Year: 2002Chemists of all types, and medicinal chemists in particular, now have their pick of positions at drug discovery centres, their shortage in the industry being reflected in the five-figure signing bonuses they can command straight out of graduate school.Editorial from Nature Reviews Drug Discovery, March 2002.Year: 2011Chemists continue to face challenges on the employment front, but one potential solution is to accept a temporary assignment. ...Yet in a job market where instability is the only constant, perhaps the best advice for those in temporary positions is to try to make lemonade out of lemons.Temporary work can provide skills, experience, and contacts that help a chemist land a permanent job. …And for those temp workers who find that they dislike their work environment or research duties, well, it’s only temporary.Chemical & Engineering News,Volume 89 Issue 50 December 12, 2011, pp. 41-433739The New York Times, 7 December 2011Financial TimesMerck bets big on ChinaDecember 6, 2011 by Rob MintoFor all the news of growth slowdowns, drug companies still love EMs.Merck, the US pharmaceutical giant, announced on Tuesday it is building a $1.5bn R&D facility in Beijing. The move follows comments on Monday from Miles White, Abbott chief executive, that companies need to “ride the wave of [EM] growth“.Speaking at the Financial Times Global Pharmaceutical and Biotech conference in London, White said that emerging market economies such as China, Brazil and India would become increasingly important revenue drivers for drug and healthcare companies.“We will be doing more of our R&D in other parts of the world [outside the US],”he told the conference. “You tend to put your investments where your revenues are.”The Merck facility will open in 2014, and will consist of 47,000 sqm of office and laboratory space. It was described by the company as an “important milestone”.。

纳米材料在医学上的应用ppt课件

纳米材料在医学上的应用ppt课件

整理ppt
15
2 .用量子点检测肿瘤细胞
Quantum dots modified with antibodies to human prostate specific membrane antigen light up murine tumors that developed from human prostate cells. Nature Biotechnology, Vol22,2004
纳米材料在生物工程及医药上的应用
整理ppt
汇报人:
1
• 为什么我们纳米材料 会广泛应用在医药上?
• 纳米材料引入医药对 医药有何影响?
• ………
整理ppt
2
• 我们都知道,目前的医疗技
术尚无法达到分子修复的水
平。而纳米医学则是在分子
水平上,利用分子工具和人
体的分子知识,创造并利用
纳米装置和纳米结构来防病
前沿科技。
整理ppt
11
2. 纳米机器人
• 纳米技术与分子生物学的结合将开创分子仿生学 新领域。 “纳米机器人”是根据分子水平的生 物学原理为设计原型,设计制造可对纳米空间进 行操作的“功能分子器件”。
整理ppt
12
纳米机器人消灭癌细 胞虚拟图
在血管中运动的纳米机器人,正在 使用纳米切割机和真空吸尘器来清 除血管中的沉积物。
一种或集成多种生物活性分子,仅用微量生理或生物采样,
即可同时检测和研究不同的生物细胞、生物分子和DNA的
特性,以及它们之间的相互作用,获得生命微观活动的规
律。生物芯片可以粗略地分为细胞芯片、蛋白质芯片(生
物分子芯片)和基因芯片(DNA芯片)等几类,都有集成、
并行和快速检测的优点,已经成为21世纪生物医学工程的

【医学PPT课件大全】 酶工程

【医学PPT课件大全】 酶工程
【医学PPT课件大全】 酶工程
第十章 同工酶与气体酶学
• 第一节 同工酶的基础知识 • 第二节 同工酶的应用 • 第三节 固氮酶的作用 • 第四节 甲烷加氧酶的作用 • 第五节 氧化CO的酶
第一节 同工酶的基础知识
一.概念:指同一种酶的多种分子形式。这些不 同的分子形式具有相同或相似的底物,催化 相同的反应
二.酶的性质
• 1.甲烷利用细菌的分类和表现形态 • 可根据所利用碳源和能源不同将甲烷利用
细菌分成:
– 专性甲烷利用细菌 – 兼性甲烷利用细菌 – 拟甲烷利用细菌
2.酶的组成
• 组分A为245KD左右的羟基化酶; • 组分B为15KD左右的调节蛋白; • 组分C为分子量为40KD左右的还原酶
3.活性中心
二.分类
• 单基因决定的同工酶 • 多基因决定的同工酶 • 复等位基因基因决定的同工酶 • 修饰同工酶
三.同工酶的结构基础
• 同工酶的一级结构的差异 • 构象变化造成同工酶的差异
四.同工酶的常用分离和测定方法
• (一) 方法
– 1 电泳 – 2 层析 – 3 热稳定性 – 4 动力学 – 5 免疫法
• 羟基化酶是一个由三种亚基组成的二聚体蛋白 • 什么是MMOB?
第四节结束
• 点击返回
第五节 氧化CO的酶
• 一.羧基养细菌的CO脱氢酶 • 二.硫酸盐还原细菌的CO脱氢酶 • 三.光养厌氧菌的CO脱氢酶 • 四.甲烷养细菌的甲烷单加氧酶
第五节结束
• 点击返回
基因表达和调控 – 3.根瘤菌结瘤因子的结构和生物合成 – 4.根瘤菌及其宿主植物的基因组学转录组学
和蛋白质组学 – 5.固氮酶的结构和功能及其化学模拟
三.固氮酶的酶学简介

课件 Medchem(2012)-14b(blockbuster drug, advertising and personalised medicine)

课件 Medchem(2012)-14b(blockbuster drug, advertising and personalised medicine)

Blockbuster Drugs对于重磅药物有争议的几个方面:重磅药物的出发点是对于社会上大多病人有效,但实际上并不是那样。

结果是大药企挣钱,而有些病人用药根本没有效果(与此相对立的是personalized medicine,这是以后药物研发的方向,有可能取代重磅药物的模式)。

对于重磅药物的追求,大药企投钱于同一类畅销药物(类似于Me-too的情况),造成资源的浪费。

目前很难出重磅药物了,研发费用高,风险大,因为对于药物的适应症要求宽,所以极有可能在临床上失败(相反,如果药物定位的适应症是有共同点的少数病人,则这个药物有可能通过临床而上市)。

目前许多重磅药物是有争议的,原因是因为药企大力的广告,扩大适应症,想把所有病人都拉进来。

这个药物的市场愈大,则副作用及事故也相对增加。

重磅药物的模式是建立在获取最大商业回报的理念上的,并不是从病人的治病来考虑的。

由于重磅药物的存在,使许多大药企过分依赖于几个产品,从资金和收入讲,风险很大。

一个药企的命运好像就在几个重磅药物上支撑着。

对于那些非专利药企业,例如Teva,Dr Reddy’s,Ranbaxy等,一直像饿狼一样在盯着重磅药物,主动破废有效的专利,或一旦等专利到期就上市,这对于有重磅药物的企业讲是致命的打击。

1关于国外药企被指控为把正常人变成病人的情况在国外有几本书,几个很典型的作者,指责大药企为了追求利润,为了扩大产品(药品)市场,利用广告(在美国和新西兰是允许在电视上做处方药广告的),重新定义疾病,扩大病人范围,把正常人也定义成病人了。

目前有争议的一个典型例子是用于治病女性性欲低下的药物,是相对于男性万艾可(Viagra)的同类市场。

辉瑞(Pfizer)在这方面投了很多钱,也招收了不少学术界的人为这个概念助威,所谓的FSD(Female Sexual Dysfunction)。

在中国,我们的一些药厂和企业还没有达到国外药企的文明水平,或者是我们政府部门管理水平的极端低下,导致了国内药物市场的混乱。

酶工程1(中国药科大学生物工程所有课件)

酶工程1(中国药科大学生物工程所有课件)
体积的活力。 • 局限性:在重复使用中,酶有损耗。
2020/8/13
( 1 )吸附法
(1)必须注意维持酶的构象,特别是活性中心的构象。 (2)酶与载体必须有一定的结合程度。酶的固定化既不影响酶的原有构象,又
能使固定化酶能有效回收贮藏,利于反复使用。 (3)固定化应有利于自动化、机械化操作。这要求用于固定化的载体必须有一
定的机械强度,才能使之在制备过程中不易破坏或受损。 (4)固定化酶应有最小的空间位阻。 (5)固定化酶应有最大的稳定性。在应用过程中,所选载体应不和底物、产物
2020/8/13
第一节 概 述
酶工程简介 酶工程(Enzyme engineering)是指通过化学
方法、酶学方法和DNA重组技术改善自然酶的 形成、结构和性质,提高酶的催化活性、降低 成本并在大规模工业化生产中应用。 主要内容: 1 酶的制备和酶与细胞的固定化 2 酶反应器的设计和放大 3反应条件的控制和优化 …….
纯化倍数=每次比活力/第一次比活力
产率%=每次总活力/第一次总活力
2020/8/13
2 酶的活力测定
1个酶活力国际单位是指在特定条件下, 1min内生成1μmol产物的酶量(或转化1 μmol 底物的酶量)。
2020/8/13
第二节 酶和细胞固定化
2020/8/13
酶固定化技术发展史
• 20世纪60年代,以色列科学家发现酶的固定化现象。 • 1969年,千畑一郎等将固定化氨基酰化酶应用于生产L-氨
或反应液发生化学反应。 (6)固定化酶的成本适中。
2020/8/13
⒊酶和细胞固定化方法
酶和细胞固定化方法
载体结合法 交联法
包埋法
网格型 微囊型
物理吸附法 离子结合法 共价结合法

【医学ppt课件】 第六章 酶(enzyme)

【医学ppt课件】 第六章 酶(enzyme)

或[IES]= [IE][S]/Ks.= [E][S] [I]/ KiKs. (5-32)

而[Eo]= [E]+[ES]+ [IE] + [IES] (5-33)
2021/1/9
• 非竟争性抑制动力学图:
• 反竟争性抑制作用:
2021/1/9
• 反竟争性抑制作用:
2021/1/9

[ES] = [E] [S] /Ks

ES解离速度 =(K2+K3) [ES] ( 5-4)
( 5-5)重排: •
2021/1/9
[ES]= [E][S]/Km (5-7) 恒态时 [E]= [Eo]- [ES]( 5-8)
将( 5-8)代入 (5-7)式,得到: [ES]=( [Eo]- [ES]) [S]/Km (5-9)
• 从(5-9)式中求解[ES]
2021/1/9
二 中间复合物学说和酶作用的过度态
• 酶 (E) 底物 (S) 酶底物复合物 (ES) 产物 (P) • E + S ≒ ES ——→ E + P
三 酶作用高效率的机制 • (一)底物的 “趋近” 和 “定向” 效应
• 趋近效应(approximation) • 定向效应(oreintation)
• [IES]=[ES] [I]/Ki= [E][S] [I]/ Ks Ki

[Eo]= [E]+[ES]+ [IE] + [IES]
(5-36) (5-37) (5-38)
2021/1/9
• 反竟争性抑制动力学图:
2021/1/9
• (三)过渡态类似物与自杀底物
2021/1/9

水溶性维生素及辅酶PPT课件

水溶性维生素及辅酶PPT课件

OHOHOH O
CH2CHCHCHCH2OPOCH2 O
N
N
NN
OH2
CH3
CO
N
N
CH3
NH
NC
NH2
O
FMN
FAD
第6页/共24页

FMN FM FM NH2 N和FAD的氧化-还原
反应

FAD
FA D H 2
+2H -2H
+2H -2H
第7页/共24页
三、 VB3(泛酸)和辅酶A(CoA)
O
C
脲 HN
NH
戊酸侧链
噻吩
H2C S
CH (CH2)4COOH
羧化酶的功能是作为CO2的递体,在生物合成中起传递和 固定CO2的作用。
第17页/共24页
生物素羧化酶的作用机制
+ HCO3-
生物素-酶
CO2-生物素酶
第18页/共24页
七、 VB11(叶酸)和四氢叶酸(FH4或 THF)
• 四氢叶酸是转一碳单位酶的辅酶,其前体是叶酸(又称为蝶酰
谷氨酸,维生素B11)。
H
N NH
H2N
H
N
N
CH2 NH H
OH H
COOH
CH2
O
CH2
C NH CH COOH
四氢叶酸的主要作用是作为一碳基团,如-CH3, -CH2-, -CHO 等(P372)的载体,参与多种生物合成过程。
第19页/共24页
八、 维生素B12与辅酶B12
• 维生素B12又称为钴胺素。维生素B12分子中与Co+相连的CN基被5’-脱氧腺苷所取代, 形成维生素B12辅酶(P377)。
  1. 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
  2. 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
  3. 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。

1⏹Regulatory affairs⏹Patents⏹Chemical process research anddevelopment Process Research and Development Process Research and DevelopmentSynthetic chemists working in the pharmaceutical industry◆Synthetic chemists working for pharmaceutical companies generally belong toone of two different tribes. Either you make new compounds (medicinal chemists), or you find new ways to make them (process chemists).◆Medicinal chemists.The new-compound people inside a company are themedicinal chemists, whose mandate is to make as many different analogs as possible while optimising their biological activities. While this can certainly require interesting chemistry, it certainly doesn't have to. Reactions straight from an introductory textbook will do nicely (very nicely, since those reactions tend to work). In fact, the shorter, easier, and less exciting the synthetic route, the better.◆Process chemists.The second tribe is the process chemists, who are chargedwith improving the medicinal chemist's synthetic routes when a compound goes into clinical trials. 'Improve‘is often synonymous with 'wad up and throw away'.The med-chem labs are biased towards reaction schemes that have the most flexibility for making analogues, but these aren't necessarily the cheapest, most scalable, and most reproducible paths for one particular compound. All of these qualities are vital in process work, though, and they have to be dealt with under some of the strictest deadlines in the whole industry.3做新药研发是一个很特殊的职业,一个人可能一生都发明不了一个新药,这种现象是被看作是正常的。

这个职业是容易让人得抑郁症的,特别是在现在这个制药企业时代,企业不断合并和裁员。

Medicinal chemist Megh Singh contributes to R&D at the Center for World Health & Medicine. Credit: Saint Louis University. Chemical & Engineering News, Volume 90 Issue 40 pp. 15-255"I once read that the best way to describe a medicinal chemist is a compulsive gambler. Every medicinal chemist thinks that the next compound is going to be the one that hits the jackpot”.Nick Hodge, founder and vice president of chemistry and technologyof a small chemical genomics firm, Amphora Discovery.(From: Louisa Wray Dalton, Medicinal chemistry, working in the fieldof drug discovery requires a broad mix of interests and skills, CEN (23 June 2003)81p53).7Chemical development:To devise a synthetic route that is straightforward, safe, cheap, efficient, and high yielding, has the minimum number of synthetic steps, and will provide a consistently high-quality product which meets predetermined specifications of purity.Process development:To ensure that the number of reactions in the synthetic route is as small as possible, and all the individual stages in the process are integrated with each other such that the full synthesis runs smoothly and efficiently on a production scale.9Impurity profiling :The regulatory authoritiesrequire that every batch of adrug product is analysed toensure that it meets the requiredspecifications, and that allimpurities are characterised,identified, and quantified. Thisnormally involves their isolationby preparative HPLC, followedby NMR spectroscopy or massspectrometry to identify theirstructure.Process Research and DevelopmentThe antihistamine drug (抗组胺药物)Terfenadine (特非那丁)is actually inactive in vitro , but in vivo it is metabolised by cytochrome P450 (CYP3A4) to an active form called Fexofenadine (非索非那丁).Terfenadine (特非那丁)had been withdrawn from the market.Terfenadine (Seldane)Fexofenadine (Allegra)NOHHO CO 2HN OH HO11The synthesis of Terfenadine (特非那丁)NOHO Cl Cl O+ClO Azacyclonol K 2CO 3, tolueneN OHHO NaBH 4, MeOH The key steps in the manufacturing of Terfenadineand Fexofenadine on commercial scalesFexofenadine process para:meta as 1:2ClOCl Cl O+Terfenadine processCl Cl O+CO 2Et CO 2Et ClO CO 2EtCl O+13KOHH 2O, MeOH, 76%C HO N CO 2HHO HgO, aq H 2SO 4MeOH, 75%C HO N CO 2CH 3OHO CH 3SO 2Cl pyridine, CH 2Cl 2, 100%MsO Azacyclonol K 2CO 3, CH 3CN 75%C HO N CO 2CH 3CO 2CH 3CO 2CH 3Br CO 2CH 3OH Pd(PPh 3)4, CuBr,Et 3N, 97%C HO N CO 2CH 3HO NaBH 4MeOH, 95%Fexofenadine (非索非那丁)An industrial process for Fexofenadine151719212325几张国内小试和中试设备的相片CPhI Shanghai 201227 The Synthesis of Sildenafil(Viagra)⏹VIAGRA®⏹Sildenafil citrate⏹1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine citrate29The Synthesis of Sildenafil (Viagra)SOCl 2, reflux SOCl 2, toluene, 50 CNN O 2N NH 3(aq), acetoneNH 3(aq)NN O 2N SnCl 2, EtOH, reflux H 2, Pd-C, EtOAcCl OH 2N ONN H 2N H 2NOEt 3N, DMAP(cat), CH 2Cl 2Pyridine, EtOAcOEtCO 2H(COCl)2, CH 2Cl 2SOCl 2, DMF(cat), EtOAcOEtClO NaOH, EtOH, H 2O 2KOBu-t , t -BuOHClSO 3HN-methylpiperazine, EtOH N-methylpiperazine, tolueneOEt NHNNN OO 2S citric acid, acetoneSildenafil.HO 2CCO 2HHOCO 2HSildenafil citrateOEt NHNNN OSO 2ClOEt NHNNN ONH N HO O O 2NOEtN HO NN H 2N O NN OEt NHNNN OO 2SNNBlack colour is for the Medicinal Chemistry Process(1990), 9.8% overall yield from the nitro pyrazole acid to the final sildenafil citrate.Blue colour is for the Optimised Medicinal ChemistryProcess (1994), 35.9% overall yield from the nitro pyrazole acid to the final sildenafil citrate.Synthesis of 1-Methyl-4-nitro-3-propyl-1H -pyrazole-5-carboxylic AcidO(CO 2Et)2, NaOEtCO 2EtOO N 2H 4, H 2OMe 2SO 4NaOH, H 2OHNO 3, H 2SO 4NH N OONN OONN HOONH N HOOO 2N31The commercial route to Pfizer’s ViagraSOCl 2, DMF(cat)toluene, refluxNH 3(aq)H 2, Pd-C, EtOAcCDI (N,N'-carbonyldiimidazole)2-ethoxy-5-(4-methyl-1-piperazinesulphonyl)benzoic acidKOBu-t , t -BuOHcitric acid 2-butanoneNN O 2N ClONN O 2NHOO NN H 2NH 2NON HONN H 2N OOEt NHNNN OO 2SSildenafilNN OEtCO 2HClSO 3, SOCl 2OEtCO 2HSO 2ClN-methylpiperazineH 2OOEtCO 2HO 2SNNNN O 2N H 2NOOEt O 2SNN.HO 2CCO 2HHOCO 2HSildenafil citrateOEt NHNNN OO 2SNNEtOAC75% overall yield from the nitro pyrazole acid to the final sildenafil citrate.直接使用天然产物作为药物上临床和上市33Over 60 g of (+)-discodermolide was prepared in 39 steps. Required 17 chromatographic purifications.The entire process took some 20 months to complete.A total of over 43 chemists participated in the concept of the synthesis, experimental design, and execution.加上Tenofovir 的生产成本例子●在这里,讲一下仿制药的价格低的好处。

相关文档
最新文档